Health in Germany
Welcome to Med-Kolleg - Health in Germany
This Health-Provider-Directory is designed to help doctors and other users to find out information on all aspects of the German health market.
We also refer international travelers requiring medical assistance to qualified doctors or specialists.
Med Kolleg is a health portal with general medicine and health topics. We have search facilities that allows you to find a hospital / clinic or practitioner in Germany from our database (physicians in Germany / hospitals in Germany). Med-Kolleg is completely independent from German insurances, hospitals and doctors.
Please note that general medical information - as provided on this website - does not replace visiting a physician or a medical emergency service, only a physician can assess the individual situation of your health.
The German Health Care System
The German health care system dates back to 1883, when nationwide health insurance became compulsory.
The German health care system has the reputation of being one of the best in the world. Medical facilities are equipped with the latest technology, an extensive network of hospitals and
doctors covers even the remotest areas of Germany. Doctors are highly qualified with a thorough education as well as a high level of qualification amongst medical staff.
Read more about the German Health System
German Health Insurance Schemes
Health insurance in Germany is a part of the social security system.
There are two types of German Health Insurance Schemes - the State Health Insurance and the Private Health Insurance. 88 percent belong to a statutory health scheme
and around nine percent are privately insured.
Read more...
Health News Germany
2010-02-03:
Daiichi Sankyo initiates largest single, double - blind, randomized, Phase III trial for treatment and prevention of recurrent venous thromboembolism
Tokyo, Japan and Edison, N.J. ( na Originaltextservice ) - First Patient Randomized and Dosed in New Trial with Factor Xa Inhibitor, Edoxaban Daiichi Sankyo Company, Limited ( TSE: 4568 ), announced today that it has initiated a new large - scale pivotal Phase III trial for edoxaban, (...) Read more...
2005-10-10:
World Mental Health Day 2005 Examines the Close Link Between Mental and Physical Health Across the Life Span
Washington D.c. ( PRN/ots ) - - Dr Benedetto Saraceno of WHO Will Keynote a Symposium to Mark 2005 WMHD in Washington D.C. The 13th World Mental Health Day ( WMHD ) will be celebrated today in many countries and this year examines the close relationship between (...) Read more...
2010-10-20:
Takeda Submits European Marketing Authorisation Application for Azilsartan Medoxomil, an Investigational Compound for the Treatment of Essential Hypertension
London and Osaka, Japan ( PRN/ots ) - Takeda Pharmaceutical Company Limited ( Takeda ) today announced that Takeda Global Research & Development Centre ( Europe ), Ltd. submitted a Marketing Authorisation Application ( MAA ) for azilsartan medoxomil ( development code: TAK - 491 ), an angiotensin II receptor blocker ( ARB ), to the European Medicines (...) Read more...
2005-10-31:
Innovative Drug Tarceva Now Available in Europe to Tackle Growing Lung Cancer Epidemic
Basel, Switzerland ( PRN/ots ) - The news that the innovative new cancer drug Tarceva( R ) ( erlotinib ) is now becoming available across the EU will provide a glimmer of hope to over 380,000 people in Europe this year who have received the devastating news that they have (...) Read more...
2007-10-03:
MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti - Infective for Treatment of Diabetic Foot Infections, From Genaera
Wellesley Hills, Massachusetts ( PRN/ots ) - - Broadens late - stage product development portfolio building on lead product candidate EcoNail in Phase 2 trial for onychomycosis MacroChem Corporation ( OTC Bulletin Board: MACM ) today announced that it has exercised the option it acquired in July, (...) Read more...
2007-04-27:
CHMP Adopts Positive Opinion for Alexion's Soliris( TM ) in Europe
Cheshire, Connecticut ( PRN/ots ) - - CHMP recommends marketing authorization for Soliris( TM ) ( eculizumab ) to treat all patients with paroxysmal nocturnal hemoglobinuria ( PNH ) - - First medicinal product to receive positive opinion from CHMP under Accelerated Assessment Procedure - Alexion Pharmaceuticals, Inc. ( Nasdaq: ALXN ) today announced (...) Read more...
2006-06-22:
New Evidence Shows MabThera Inhibits Joint Damage in Patients With Rheumatoid Arthritis
Basel, Switzerland and Amsterdam ( PRN/ots ) - - First RA Drug to Achieve These Results in Patients With an Inadequate Response to Currently Available Treatments New data presented at the EULAR meeting ( European League Against Rheumatism ) show for the first time that MabThera (...) Read more...
2008-11-10:
First Study in Real - Life Setting Confirms That Once - Monthly Mircera Keeps Haemoglobin Levels Within a Tight Range
Basel, Switzerland, November 10 ( PRN/ots ) - - Results Demonstrate Effective and Simplified Approach to Anaemia Management in Chronic Kidney Disease Patients on Dialysis Interim study results from 90 renal centres in Germany confirm for the first time that in a real - life (...) Read more...
2009-02-19:
CRESTOR Cuts Risk of Stroke by Nearly Half in JUPITER Study
San Diego, California ( PRN/ots ) - A new analysis from the JUPITER study presented today at the International Stroke Conference ( ISC ) in San Diego, California, describes details of the stroke data according to gender, ethnicity and baseline risk factors. This data adds to the primary (...) Read more...
2008-04-14:
Botaneco Announces Launch of Second Generation Oleosome Product
Calgary, Canada ( PRN/ots ) - - Natural Hydresia( TM ) G2 Offers Enhanced Formulation Flexibility With a Globally Accepted Preservative System Botaneco, a wholly owned subsidiary of SemBioSys Genetics Inc. ( TSX: SBS ), focused on the development and commercialization of oleosome technology in personal care, OTC and (...) Read more...
Surveys / Reports
Surveys / Reports
Notifiable Disease Surveillance and Practicing Physicians
Primary care physicians in Germany are essential participants in infectious disease surveillance through mandatory reporting.
In 2001, a new infectious disease control law (IfSG) was implemented in Germany. Most diseases are to be reported to the local county (Landkreis) health department from where they are reported by the state (Land) to the national surveillance institute (Robert Koch Institute). The IfSG also introduced national case definitions for notifiable diseases.
The aim of this study was to identify the needs and attitudes of primary care physicians towards public health surveillance.
These issues were investigated in a questionnaire survey among 8,550 randomly sampled physicians in Germany in 2001.
» Krause G, Ropers G, Stark K. Notifiable disease surveillance and practicing physicians. Emerg Infect Dis [serial on the Internet]. 2005 Mar
Latest Entries / Latest Changes
Hospitals: latest entries / changes:
|
Vivantes Klinikum Neukölln Clinic für Kinder- and Jugendpsychiatrie, psychotherapy and Psychosomatik Vivantes Klinikum Neukölln 12351 Berlin Neukölln (Berlin) (changed: 2012-04-09) |
|
Klinikum Delmenhorst gGmbH regular hospital for acute cases Klinikum Delmenhorst gGmbH 27753 Delmenhorst (Lower Saxony) (changed: 2011-12-25) |
3330 entries in clinics directory.
DocSearch: latest entries / changes:
|
Eugenie Peresechenski Eugenie Peresechenski 63069 Offenbach am Main (Hesse) (changed: 2013-01-30) |
|
Dr. med Britta Schmidt Dr. med Britta Schmidt 12159 Berlin Schöneberg/Friedenau (Berlin) (changed: 2013-01-27) |
Dentist Search: latest entries / changes:
|
R. Nowrozi R. Nowrozi 10713 Berlin Wilmersdorf (Berlin) (changed: 2013-04-19) |
|
Dr. Dominic Sprothen Dr. Dominic Sprothen 41063 Mönchengladbach Eicken (Nordrhein-Westfalen) (changed: 2013-04-14 ) |



